Malvern’s Neuronetics Prices $30 Million Stock Offering, With Plans to Pay Down Debt

Published · Updated · 5 min read · Greater Philadelphia
Malvern’s Neuronetics Prices $30 Million Stock Offering, With Plans to Pay Down Debt

Neuronetics, a Malvern, Pennsylvania-based mental health technology and treatment company, has priced a public offering of common stock expected to raise about $30 million, the company announced on November 10, 2026. Neuronetics plans to use part of the proceeds to repay a portion of its term loan, a step tied to easing financial covenants on its credit facility.

Inside the Offering

Neuronetics is selling 18,750,000 shares of common stock at $1.60 per share. Underwriters have a 30-day option to buy up to 2,812,500 additional shares. The roughly $30 million in gross proceeds is before underwriting discounts, commissions, and other expenses. The offering was expected to close on or about November 12, 2026.

William Blair is the lead bookrunning manager, with BTIG and Canaccord Genuity serving as additional bookrunners.

Why the Raise Matters

On November 5, Neuronetics amended its credit facility with Perceptive Credit Holdings IV, LP to reduce certain revenue covenants. The amendment only takes effect if the company meets several conditions by November 30, 2026, including prepaying at least $15 million on the loan. Neuronetics says that if those conditions are met, the reduced covenants will resolve the going concern risk flagged in its recent quarterly filings.

Beyond the loan repayment, the company plans to use the proceeds for general corporate purposes. These could include sales and marketing, research and development, potential acquisitions or new healthcare practices, inventory, and working capital.

About Neuronetics

Neuronetics develops the NeuroStar Advanced Therapy System, a non-drug, noninvasive transcranial magnetic stimulation (TMS) treatment. The U.S. Food and Drug Administration (FDA) has cleared NeuroStar for adults with major depressive disorder (MDD); as an add-on treatment for adults with obsessive-compulsive disorder; to reduce anxiety symptoms in adults with MDD; and as a first-line add-on treatment for MDD in patients ages 15 to 21. Through its Greenbrook TMS clinic network, the company also offers SPRAVATO® (esketamine) nasal spray for adults with treatment-resistant depression. For safety information and indications for use, visit NeuroStar.com.

Safe Harbor / Forward-Looking Statements

Certain statements in this press release include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and “forward-looking information” within the meaning of applicable Canadian securities laws. Statements in this press release that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “may,” “will,” “would,” “should,” “expect,” “plan,” “design,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “outlook” or “continue” as well as the negative of these terms and similar expressions. Forward-looking statements in this press release include, but are not limited to, statements regarding the filing of the final prospectus supplement and the accompanying prospectus relating to the offering, anticipated closing of the offering, the gross proceeds, the intended use of proceeds, including the prepayment of a portion of the outstanding term loan under the Credit Facility with Perceptive Credit Holdings IV, LP, the satisfaction of the conditions precedent to the effectiveness of the Perceptive Sixth Amendment, and the completion of the offering on the anticipated terms or at all. There can be no assurance that this offering will close or that the Company will receive the net proceeds therefrom. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those projected, including the anticipated timing of the offering, market conditions and satisfaction of customary closing conditions for the offering and our ability to satisfy the conditions precedent to the Perceptive Sixth Amendment on or before November 30, 2026. Other risks and uncertainties include, without limitation, risks and uncertainties related to: the effect of the transaction with Greenbrook on our business relationships; operating results and business generally; our ability to execute our business strategy; our ability to achieve or sustain profitable operations due to our history of losses; our reliance on the sale and usage of our NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of our salesforce; our ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using our products; physician and patient demand for treatments using our products and services; developments in respect of competing technologies and therapies for the indications that our products and services treat; product defects; our ability to obtain and maintain intellectual property protection for our technology; developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; potential effects of evolving and/or extensive government regulation; the terms of our credit facility; our self-sustainability; existing cash balance; our ability to achieve positive cash flows; and our ability to continue as a going concern. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. For a discussion of these and other related risks, please refer to the Company’s recent filings with the U.S. Securities and Exchange Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov, including, without limitation, the factors described under the heading “Risk Factors” in Neuronetics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as may be updated or supplemented by subsequent reports that Neuronetics has filed or files with the SEC. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company’s expectations.

Investor Contact:

Mark Klausner ICR Healthcare 443-213-0499 [email protected]

Media Contact:

EvolveMKD 646-517-4220 [email protected]

Source: Neuronetics on November 11, 2026. Republished with credit to the original author. Read the original release.